Breaking News

GSK Sells Thrombosis Drugs to Aspen

To divest Arixtra and Fraxiparine brands for $1.1 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline has agreed to sell its thrombosis drug brands and a related factory to Aspen Pharmacare for approximately $1.1 billion. GSK owns an 18.6% stake in Aspen, South Africa’s largest generic drug company.
 
The divestment includes the Arixtra and Fraxiparine brands, whose worldwide sales are declining as new drugs are set to launch. GSK plans to retain the rights to these brands in China, India and Pakistan.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters